Stockscreener 앱 받기
1.9998
0.01%
-0.0002
전일 마감가:
$2.00
열려 있는:
$2.02
하루 거래량:
49,736
Relative Volume:
0.67
시가총액:
$5.76M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-14.54%
1개월 성능:
+21.57%
6개월 성능:
-83.62%
1년 성능:
-96.74%
1일 변동 폭
$2.00
$2.0941
1주일 범위
$2.00
$2.82
52주 변동 폭
$1.52
$70.00
Autonomix Medical Inc Stock (AMIX) Company Profile
명칭
Autonomix Medical Inc
전화
832-277-7816
주소
21 WATERWAY AVENUE, SUITE 300, THE WOODLANDS
AMIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMIX
Autonomix Medical Inc
|
2.00 | 5.76M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
132.33 | 224.65B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.36 | 151.13B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.53 | 139.34B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
83.47 | 108.80B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
75.36 | 44.25B | 5.54B | 4.18B | 259.90M | 7.00 |
Autonomix Medical Inc 주식(AMIX)의 최신 뉴스
Autonomix reports significant pain relief in cancer trial - Investing.com Australia
Autonomix Highlights Compelling Patient Testimonial Showing - GlobeNewswire
Breakthrough Cancer Pain Treatment Eliminates Opioid Use in 100% of Responding Patients, Trial Shows - Stock Titan
Mariner LLC Sells 11,756 Shares of Autonomix Medical, Inc. (NASDAQ:AMIX) - Defense World
It is Poised to be a Bull Market for Autonomix Medical Inc (AMIX) - Sete News
Autonomix Medical, Inc. Announces Successful Initial Trial Phase and Plans for Market Expansion Study in Pancreatic Cancer Pain Management - Nasdaq
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor 'What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain - The Manila Times
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain - GlobeNewswire
Autonomix Medical Pain Treatment Trial Success Leads to Cancer Market Expansion | AMIX Stock News - Stock Titan
Autonomix Medical Inc (AMIX) Outlook: Looking Back For Insights - Stocksregister
Maxim Group Initiates Coverage on Autonomix Medical (NASDAQ:AMIX) - Defense World
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlo - GuruFocus
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic C - GuruFocus
How is AMIX’s stock performing after recent trades? - uspostnews.com
Autonomix Medical Inc (AMIX) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
Autonomix provides update on initial phase on delivering transvascular energy - TipRanks
Autonomix advances pain treatment in cancer trials - Investing.com Australia
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlook | AMIX Stock News - GuruFocus
Autonomix Medical Reports Successful Phase 1 Trial Results for Pain Management in Pancreatic Cancer, Initiates Phase 2 Study - Nasdaq
Autonomix Medical, Inc. Reports Positive Outcomes in - GlobeNewswire
Revolutionary Cancer Pain Treatment Shows 100% Success Rate: Autonomix Medical's Breakthrough Trial Results - Stock Titan
Maxim Group Initiates Coverage of Autonomix Medical (AMIX) with Buy Recommendation - Nasdaq
Maxim Group Initiates Coverage on Autonomix Medical With Buy Rating, $5 Price Target - marketscreener.com
Autonomix Medical, Inc. to Present Innovative Neural Ablation Technology at EuroPCR 2025 - Nasdaq
Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR - GlobeNewswire
Revolutionary Neural Ablation Technology for Cancer Pain Management Showcased at Leading Medical Conference - Stock Titan
Autonomix Medical announces inducement grant - Medical Buyer
Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Autonomix Medical Expands Team with Strategic 5,000-Share Stock Option Grant to New Key Employee - Stock Titan
Autonomix Medical secures new European patent for nerve tech By Investing.com - Investing.com South Africa
Autonomix Medical Granted European Patent For Catheter-Based Neuromodulation Technology - Nasdaq
Autonomix Gains European Patent for Catheter-Based Tech - Medical Product Outsourcing
Autonomix Medical secures new European patent for nerve tech - Investing.com
Autonomix Medical Granted New European Patent For Proprietary Catheter-Based Technology - marketscreener.com
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology - GlobeNewswire
Medical Breakthrough: Autonomix's New EU Patent Powers Multi-Condition Treatment Platform - Stock Titan
Autonomix (AMIX) Secures European Patent for Neuromodulation Inn - GuruFocus
Autonomix stock plunges to 52-week low of $1.52 amid steep annual decline - Investing.com Australia
Autonomix stock plunges to 52-week low of $1.52 amid steep annual decline By Investing.com - Investing.com South Africa
Analyzing Globus Medical (NYSE:GMED) & Autonomix Medical (NASDAQ:AMIX) - Defense World
Autonomix to begin U.S. clinical studies for FDA approval By Investing.com - Investing.com South Africa
Autonomix to begin U.S. clinical studies for FDA approval - Investing.com
Autonomix Medical, Inc. Engages Leading Medical Experts to - GlobeNewswire
Top Medical Experts Join Forces to Advance Revolutionary Pancreatic Cancer Pain Treatment - Stock Titan
Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO) - GlobeNewswire
Revolutionary Pancreatic Cancer Pain Treatment: Autonomix Medical Reveals First Clinical Results at ECIO 2025 - Stock Titan
Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Update - Defense World
Patent Granted to Autonomix Medical for Sensing Data Collection - Medical Product Outsourcing
Autonomix stock plunges to 52-week low of $1.81 amid market challenges By Investing.com - Investing.com South Africa
Autonomix stock plunges to 52-week low of $1.81 amid market challenges - Investing.com Australia
Financial Analysis: INVO Bioscience (NASDAQ:INVO) & Autonomix Medical (NASDAQ:AMIX) - Defense World
Autonomix Medical Inc (AMIX) 재무 분석
Autonomix Medical Inc (AMIX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
9.38%
0.12%
자본화:
|
볼륨(24시간):